PART THE CLOUD

alz.org/partthecloud

Impact Report 2021
Dear Friends:

In 2012, after losing my father to Alzheimer’s, I partnered with the Alzheimer’s Association to found Part the Cloud with a singular mission: to fund research with the highest probability of slowing, stopping or ultimately curing Alzheimer’s disease. Since then, my mother was diagnosed with Alzheimer’s and lost her battle in November of 2019. After watching both of my parents suffer from this disease, I have made it my life’s mission to end Alzheimer’s so that the next generation is not impacted the way my siblings and I have been.

Since our inception, I have been overwhelmed by the support we have received from so many, which has allowed us to grow from a local Bay Area event into a global movement, funding 60 clinical trials across the globe. Few Alzheimer’s research funding supports earlier phase studies needed to test drug treatments in humans and Part the Cloud addresses this critical gap, supporting early phase clinical studies and helping accelerate the transition of findings from the laboratory into possible therapies.

Part the Cloud continues to make record-breaking advancements through the funds we have raised and I am thrilled to share with our community that Part the Cloud has now generated over $65 million dollars. I am hopeful and optimistic that these funds will get us one step closer to finding a treatment or cure for Alzheimer’s disease in our lifetime.

Part the Cloud not only provides key funding for early-phase clinical trials, but we also serve as a catalyst in helping researchers receive additional funding for their work. After receiving initial funding from PTC, grant recipients have gone on to receive $940 million dollars in follow-on funding from the federal government, venture capital firms and other sources.

Every research grant awarded through Part the Cloud is moving innovative research in treatment and possible prevention forward. Every single dollar raised through Part the Cloud moves possible treatments closer to our doctors’ offices. Part the Cloud is truly making a difference in the field of Alzheimer’s research and I am grateful to our generous supporters for their commitment to our mission.

Thank you for your steadfast support, and together, we will Part the Cloud!

Warmly,

Mikey Hoag

Founder, Part the Cloud
Part the Cloud fuels and accelerates bold, brave research across the globe.

Michael Weiner, M.D. University of California at San Francisco - San Francisco, CA
"Part the Cloud supported, in part, the Whole Genome Sequencing Alzheimer’s Disease Neuroimaging Initiative (WGS-ADNI), a project to sequence the whole genome of more than 800 individuals."

METABOLIC FUNCTION

Stephen Cunnane, Ph.D. University of Sherbrooke - Quebec, Canada
Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET
*Two-time grant winner*

Stephen Cunnane, Ph.D. University of Sherbrooke - Quebec, Canada
RCT with a New Ketogenic Salt in MCI
*Two-time grant winner*

Mitchel Kling, M.D. University of Pennsylvania - Philadelphia, PA
A biomarker-based trial in MCI/AD

Stefano Sensi, M.D., Ph.D. Universita degli Studi Gabriele d’Annunzio di Chieti e Pescara - Chieti, Italy
Extenzin-Based Therapy for MCI Subjects

Russell Swerdlow, M.D. University of Kansas Medical Center - Fairway, KS
Trial of Oxaloacetate in Alzheimer’s Disease (TOAD) Study

Paul Edison, M.B.B.S, F.R.C.P., Ph.D. Imperial College London - London, United Kingdom
Evaluating Oral Semaglutide as a Treatment for Alzheimer’s Disease
*Two-time grant winner*

Giulio Maria Pasinetti, M.D., Ph.D. Icahn School of Medicine at Mount Sinai - New York, NY
BDPP Treatment for Mild Cognitive Impairment and Prediabetes

AMYLOID AND TAU

Adam L. Boxer, M.D., Ph.D. University of California at San Francisco - San Francisco, CA
Phase I Multiple Ascending Dose Trial of the MT Stabilizer TPI-287 for AD

Dale E. Bredesen, M.D. Buck Institute for Research on Aging - Novato, CA
An Exploratory Safety, PK/PD, and Preliminary Efficacy Study of F03 in MCI

Tim West, Ph.D. C2N Diagnostics - St. Louis, MO
A Single Ascending Dose Double Blinded Placebo Controlled Study of C2N-8E12

Dieter Willbold, Ph.D. Research Center Juelich GmbH - Jülich, Germany
Placebo Controlled Multi-Ascending Dose [Targeting Protein Aggregation] Phase 1 Study in Healthy Volunteers
IMMUNE RESPONSE, MISFOLDED PROTEINS AND GROWTH FACTORS

**Steven Arnold, M.D.** Massachusetts General Hospital - Boston, MA
*BCG Immunization Effects on Biomarkers of Inflammation/Immune Response and Alzheimer’s Disease*

**Franz Hefit, Ph.D.** Proclara Biosciences - Cambridge, MA
*Phase 1 Study with NPT088, a Fusion Protein to Treat Alzheimer’s Disease*

**Joseph Foss, M.D.** NeuroTherapia, Inc. - Cleveland, OH
*A Phase I Single Ascending Dose Safety and Pharmacokinetic Study of NTRX-07*

**John Sedivy, Ph.D.** and **Stephen Salloway, M.D., M.S.** Brown University - Providence, RI
*Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of Alzheimer’s Disease*

**Mark Tuszniski, M.D.** University of California at San Diego - San Diego, CA
*A Clinical Trial of BDNF Gene Therapy in Alzheimer’s Disease*

**Linda Van Eldik, Ph.D.** University of Kentucky - Lexington, KY
*Phase 1b MAD Study of a Novel Drug (MW189) Targeting Neuroinflammation*

**Manfred Windisch, Ph.D.** NeuroKine Therapeutics, LLC - Philadelphia, PA
*Phase 1 Study of MW150: Novel Stress Kinase Inhibitor Candidate*

EXPENSES

Part the Cloud keeps expenses low to ensure that over 95.8% of funds raised directly support the most groundbreaking Alzheimer’s research.

**Total Expenses**
$2,771,451.72

**Total Revenues**
$65,748,956.08

VASCULAR AND OXIDATIVE STRESS

**Whitney Wharton, Ph.D.** Emory University - Atlanta, GA
*Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s*

**Krista Lanctôt, Ph.D.** Sunnybrook Research Institute - Toronto, Canada
*Linking GSH and Cognitive Response: A Pilot Phase 2a Study of NAC in VCIND*
*Two-time grant winner*

CELL SIGNALING AND COMMUNICATION

**Frank Longo, M.D.** Stanford University, and **Anne Longo,** Pharmatrophix, Inc. - Stanford, CA
*Phase I Trial for P75 Receptor Ligand*

**Paul A. Newhouse, M.D.** Vanderbilt University - Nashville, TN
*Phase 1 Testing of a Muscarinic M1 PAM for Alzheimer’s Disease*
*Two-time grant winner*

**Keith Vossel, M.D., M.Sc.** University of California at San Francisco and Gladstone Institute for Neurological Disease - San Francisco, CA
*Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability*

**Charbel Moussa, Ph.D.** Georgetown University - Washington, D.C.
*Bosutinib Effects on Safety, Biomarkers and Clinical Outcomes in DLB*

**Ahmad Salehi, M.D., Ph.D.** Palo Alto Institute for Research and Education, Inc. - Palo Alto, CA
*Improving β2 Adrenergic Signaling in Alzheimer’s Disease*

**Nawaf Yassi, M.D., Ph.D.** University of Melbourne - Parkville, Australia
*S-Adenosyl Methionine for Alzheimer’s Disease*

**Maurice Zauderer, Ph.D.** Vaccinex, Inc. - Rochester, NY
*SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease*

**James Kirkland, M.D., Ph.D.** Mayo Clinic - Rochester, MN
*ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer’s Disease*

**Maurice Zauderer, Ph.D.** Vaccinex, Inc. - Rochester, NY
*SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease*
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>QIN-100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nucleoside reverse transcriptase inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibody to block SEM4D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bosanabin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XPRO1595</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mGluR5 SAM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MW150</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sativex*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Senecapoc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesenchymal Stem Cell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GM-CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF Gene Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPT088*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDPP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPI-287*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FO3*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBC-Ab002</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulse modulation device</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-invasive Deep Brain Stimulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CpG ODN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>transcranial Direct Current Stimulation (tDCS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EI1071</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verdirstat</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LM11A-31-BH5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ML-PAM VU319</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MW189</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTRX-07</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCCF-3012</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxaloacetate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C2N-8E12(ABBV-8E12)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levetiracetam</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dasatinib and Quercetin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAMe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allopregnanolone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Bacillus Calmette–Guerin) vaccination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Semaglutide</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketone energy drink</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NDX-1017</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGCG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perindropil</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maraviroc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valacyclovir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3D-959</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gamma Entrainment Using Sensory Stimuli (GENUS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phosphodiesterase inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rapamycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IW-6463</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MET-FINGER-APOE (Metformin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Letrozole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>transcranial photobiomodulation (t-PBM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADNI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Studies not advanced

Getting potential treatments faster: Propelling high-risk, high-reward research into clinical trials that are aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia.
RESCUE AND NEURODEGENERATION

The Part the Cloud to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease challenge aims to accelerate the discovery and testing of innovative compounds to be used for interventions in the earliest stages of neurodegeneration—dementia—Alzheimer’s disease. Presently, there are no effective interventions to delay or prevent the progression of the neurodegenerative processes that underlie the disabling symptoms of Alzheimer’s dementia.

From 45 proposals submitted from two countries, six researchers were awarded $1 million each to develop their proposals over a two-year period.

- Roberta Diaz Brinton, Ph.D. University of Arizona - Tucson, AZ
  Advancing Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s

- Rafael de la Torre, PharmD, Ph.D. Institute Mar of Medical Investigations - Barcelona, Spain
  Cognitive Decline in Early Stages of AD After EGCG and a Multimodal Therapy

- Xue Hua, Ph.D. Athira Pharma, Inc. - Seattle, WA
  Phase 2a Alzheimer’s Trials of a Novel Neurotrophic Activator, NDX-1017

- Paul A. Newhouse, M.D. Vanderbilt University - Nashville, TN
  M1-PAM VU319 Effects on Network Connectivity in MCI: A POC Study
  *Two-time grant winner*

- Stephen M. Strittmatter, M.D., Ph.D. Yale University - New Haven, CT
  Silent Allosteric Modulation of mGluR5 for Alzheimer’s Disease

- Raymond Tesi, M.D. INmune Bio - La Jolla, CA
  A biomarker directed study to reduce inflammation in Alzheimer’s disease

NEUROINFLAMMATION

A first-of-its kind competition, the Part the Cloud Neuroinflammation Challenge was created to accelerate therapeutics and deepen understanding of neurodegeneration to be used in early clinical trials. Scientists around the world were invited to submit proposals that could translate into human trials of treatments targeting neuroinflammation with the goal of improving cognition in individuals with neurodegenerative diseases.

From 60 proposals submitted from 14 countries, four researchers were awarded $1 million each to develop their proposals over a two-year period. After two years, projects were evaluated, and the most outstanding project was awarded an additional $3 million to take it and the field to the next level.

- Anthony Oliva, Ph.D. Longeveron, LLC - Miami, FL
  Mesenchymal Stem Cell Therapy for Neuroinflammation in Alzheimer’s Disease
  *After two years, this study was shown to have made the most progress and received an additional award of $3 million.*

- Anthony Oliva, Ph.D. Longeveron, LLC - Miami, FL
  Clinical Evaluation of Allogenic Mesenchymal Stem Cells for Mild Alzheimer’s Disease
  *Two-time grant winner*

- Huntington Potter, Ph.D. University of Colorado at Denver - Denver, CO
  Safety & Efficacy of GM-CSF/Leukine in Mild-to-Moderate Alzheimer’s Disease

- Isidro Ferrer, M.D., Ph.D. Center for Networked Biomedical Research on Neurodegenerative Diseases - Barcelona, Spain
  Sativex in MCI Patients at High Risk of Developing Alzheimer’s Disease *Study not advanced*

- John M. Olichney, M.D. University of California at Davis - Davis, CA
  Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer’s Disease

CHALLENGES
PART THE CLOUD AND BILL GATES PARTNERSHIP
2020 CHALLENGE

In late 2019, Part the Cloud announced an exciting partnership with Bill Gates, with the goal to double our investment in Alzheimer’s research to $60 million. The Alzheimer’s Association, through Part the Cloud, raised over $20 million, and once we reached that mark, Bill Gates provided a $10 million match, allowing us to double our clinical research investment to over $60 million in just one year.

This funding allows us to propel high-risk, high-reward research aimed at uncovering underlying brain cell changes, timely diagnosis and new treatments for Alzheimer’s and all dementia. These research grants focus on the following three topic areas:

<table>
<thead>
<tr>
<th>Mitochondria</th>
<th>Autophagy / Clearance</th>
<th>Vascular Contributions</th>
</tr>
</thead>
<tbody>
<tr>
<td>How brain cells use energy and fuel (mitochondria, bioenergetics and metabolism)</td>
<td>How brain cells remove waste and debris to avoid protein clumping</td>
<td>How blood supply in the brain is maintained</td>
</tr>
</tbody>
</table>

From 128 ideas submitted from 18 countries, over $30 million was awarded among 19 researchers to further develop their proposals over 3 years.

- David Celermajer, M.D., Ph.D. The Brain Protection Company - Paddington, Australia
  Phase 1 Study of a Novel Device Reducing Vascular Contributions to Dementia

- Sudha Seshadri, M.D. University of Texas Health Science Center at San Antonio - San Antonio, TX
  Phase 2 Trial of Rapamycin for Alzheimer’s Disease

- Krista Lanctôt, Ph.D. Sunnybrook Research Institute - Toronto, Canada
  Exercise as a primer for excitatory stimulation in VCIND (EXPRESS-V)
  *Two-time grant winner*

- Eti Yoles, Ph.D. and Michal Schwartz, Ph.D. ImmunoBrain Checkpoint, Inc. - New York, NY
  IBC-Ab002 - Immune Checkpoint Blockade to Combat Alzheimer’s Disease

- Anat Biegon, Ph.D. The Research Foundation of SUNY-SUNY at Stony Brook - Stony Brook, NY
  Aromatase inhibition in Alzheimer’s disease: Phase 2

- Thomas Wisniewski, M.D. New York University School of Medicine - New York, NY
  Phase 1 Clinical Trial of Innate Immunity Stimulation via TLR9 in Early AD

- Christopher Winrow, Ph.D., Cyclerion Therapeutics, Inc. - Cambridge, MA
  Phase 2 study of CNS sGC stimulation in AD with vascular features

- Paul Edison, M.B.B.S, F.R.C.P., Ph.D. Imperial College London - London, United Kingdom
  Mitochondrial function and BBB leakage as a novel treatment for Alzheimer’s
  *Two-time grant winner*

- Alireza Faridar, M.D. The Methodist Hospital Research Institute - Houston, TX
  Regulatory T cells as a novel therapeutic target in Alzheimer’s Disease

- John Didsbury, Ph.D. T3D Therapeutics, Inc. - Research Triangle Park, NC
  The PIONEER Study: A Phase 2 Trial of T3D-959 in Alzheimer’s Subjects

- Nir Grossman, Ph.D. Imperial College London - London, United Kingdom
  Non-Invasive Deep Brain Stimulation for Alzheimer’s Disease

- Hung-Kai Chen, M.D., Ph.D. Elixiron Immunotherapeutics Inc. - Taipei, Taiwan
  CSF1R inhibitor EI071 for modulating microglia-associated neuroinflammation

- Einor Ben Assayag, Ph.D. and Hen Hallevi, M.D. Tel Aviv Sourasky Medical Center - Tel-Aviv, Israel
  Safety and Efficacy of Maraviroc in Vascular Cognitive Impairment

- Davangere Devanand, M.D. Research Foundation for Mental Hygiene, Inc. at New York State Psychiatric Institute - New York, NY
  Anti-viral treatment in mild cognitive impairment

- Dan Iosifescu, M.D. New York University School of Medicine - New York, NY
  Photobiomodulation for Early Stage Alzheimer Disease (PhESAD)

- Miia Kivipelto, M.D., Ph.D. Imperial College London - London, United Kingdom
  Prevention of Alzheimer’s disease using gamma entrainment

- Lyndon Lien, Ph.D., M.B.A. Qinotto, Inc. - Hillsborough, CA
  Small molecule lysosome activator for the treatment of neurodegeneration

- Peter Ljubenkov, M.D. University of California, San Francisco - San Francisco, CA
  Veri-T: A phase I Placebo-Controlled Trial of Verdiperstat in FTLD-TDP

From 128 ideas submitted from 18 countries, over $30 million was awarded among 19 researchers to further develop their proposals over 3 years.
“Part the Cloud propels the global research community and allows it to explore innovative avenues of research that can accelerate needed treatments,” said Maria C. Carrillo, Ph.D., chief science officer, Alzheimer’s Association. “Bill Gates and Mikey Hoag’s commitment to the Alzheimer’s Association demonstrates the urgency with which we must pursue innovative ideas that could be game changers for the tens of millions affected by Alzheimer’s disease worldwide.” Part the Cloud is part of the Alzheimer’s Association’s robust global research platform, the largest nonprofit research program focused on Alzheimer’s and all other dementia. At any given moment, the Association’s research program actively brings together government, academia, industry and philanthropists to support the efforts of researchers and accelerate science to develop potential treatments.

Please consider making a donation to support Part the Cloud and our mission to find a treatment or cure for Alzheimer’s disease in our lifetime.

Learn more and make a donation at [alz.org/partthecloud](alz.org/partthecloud)

**JOIN US. TOGETHER, WE WILL PART THE CLOUD**

|$65 million| $940 million| 60 projects |
|since 2012| follow-on funding| worldwide|

[alz.org/partthecloud](alz.org/partthecloud)